{"product_id":"dishmangroup-marketing-mix","title":"Dishman Carbogen Amcis Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Dishman Carbogen Amcis crafts product innovation, tiered pricing, targeted distribution, and scientific-focused promotion to serve pharmaceutical clients and CRO partners—this snapshot only hints at the strategic depth. Get the full, editable 4Ps Marketing Mix Analysis for data-driven insights, presentation-ready slides, and practical recommendations to benchmark or replicate their success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive CDMO Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis offers end-to-end CDMO services across drug discovery to commercial supply, handling API synthesis, formulation, sterile fill-finish and scale-up; in 2024 CDMO revenue was €215M, up 12% YoY, with capacity across 6 GMP sites and \u0026gt;1,200 scientists—so clients cut handoffs and shorten timelines by ~30% versus multi-vendor routes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized High Potency API Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis produces High Potency APIs (HPAPIs) with specialized containment and handling; its 2024 report shows HPAPI revenue grew 18% to $120M, driven by oncology projects needing isolators and closed systems. Facilities use multi‑kg containment tech and automated reactors to run complex chemistries while meeting ISO 8\/7 and OEL (occupational exposure limit) controls, lowering batch incident rates to \u0026lt;0.2%. This niche capability draws high-value biotech deals, where CDMO HPAPI margins typically exceed 25%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVitamin D and Analogues Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis' Vitamin D and analogues portfolio — including calcitriol and cholecalciferol intermediates — accounts for roughly 18% of 2024 revenue (about $72M of $400M total), supplying pharma and nutraceutical customers worldwide.\u003c\/p\u003e\n\u003cp\u003eThe business claims market-leader status in cholesterol-derived steroid APIs, supported by GMP facilities in India and Switzerland and \u0026gt;60% recurring sales, giving steady cash flow that offsets cyclic custom-synthesis projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Drug Product Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDishman Carbogen Amcis (DCA) pairs API manufacturing with integrated drug product development, offering formulation and finished-dose manufacture—sterile liquid filling, lyophilization, and solid orals—for clinical and commercial supply.\u003c\/p\u003e\n\u003cp\u003eThis one-stop model shortens timelines and supply-chain risk; in 2024 DCA reported ~15% revenue from drug-product services and capacity for multi‑tonne solid-orals plus dedicated sterile and lyophilization suites.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSterile liquid filling, lyophilization, solid orals\u003c\/li\u003e\n\u003cli\u003eClinical-to-commercial scale capacity\u003c\/li\u003e\n\u003cli\u003e~15% 2024 revenue from drug-product services\u003c\/li\u003e\n\u003cli\u003eReduced supply-chain steps and faster timelines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustom Synthesis and Process Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDishman Carbogen Amcis offers bespoke chemical synthesis to solve complex molecular challenges for drug developers, emphasizing process R and D that raised route yields by up to 20% in 2024 and cut per-kg costs by ~15% on average.\u003c\/p\u003e\n\u003cp\u003eThe team scales new chemical entities to production, supporting time-to-clinic reductions of 3–6 months and enabling CMOs to meet demand spikes with \u0026lt;125‑tonne annual capacity across key sites.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e20% yield improvement (2024)\u003c\/li\u003e\n\u003cli\u003e~15% cost reduction per kg\u003c\/li\u003e\n\u003cli\u003e3–6 months faster scale-up\u003c\/li\u003e\n\u003cli\u003e125 tonne annual site capacity\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDCA: €400M CDMO powerhouse — high‑margin HPAPI, 6 GMP sites, 20% yield gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDCA offers end-to-end CDMO services (API to finished dose), 6 GMP sites, \u0026gt;1,200 scientists; 2024 revenue €215M CDMO, $120M HPAPI, $72M Vitamin D (18%); HPAPI margins \u0026gt;25% and \u0026lt;0.2% batch incident rate; drug-product = ~15% revenue, multi‑tonne solid capacity and sterile\/lyo suites; R\u0026amp;D improved yields 20% and cut per‑kg costs ~15%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$400M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO revenue\u003c\/td\u003e\n\u003ctd\u003e€215M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHPAPI revenue\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVitamin D revenue\u003c\/td\u003e\n\u003ctd\u003e$72M (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug-product share\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites \/ staff\u003c\/td\u003e\n\u003ctd\u003e6 GMP sites \/ \u0026gt;1,200 scientists\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYield improvement\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-kg cost reduction\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Dishman Carbogen Amcis’s Product, Price, Place, and Promotion strategies—grounded in real practices and competitive context for practical benchmarking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Dishman Carbogen Amcis’ 4Ps in a concise, structured format to ease leadership briefings and cross‑functional alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Global Manufacturing Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis operates manufacturing sites across Switzerland, France, India, the United Kingdom, and China, combining high-cost Swiss\/UK technical hubs with lower-cost Indian and Chinese plants to save ~20–30% on COGS for large-scale chemo-processes (company filings, 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwiss-Based Research and Development Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Swiss R\u0026amp;D hubs act as Dishman Carbogen Amcis primary centers for high-end research, development, and small-scale clinical manufacturing, handling ~60% of the company’s early-stage projects in 2024; they sit near Basel and Zurich pharma clusters and tap Switzerland’s 5.2% pharma R\u0026amp;D workforce density, ensuring access to top talent and CRO partners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndian Production for Scale and Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis concentrates large-scale commercial and intermediate manufacturing in India to cut operating costs; Indian sites accounted for roughly 65% of group production capacity in 2024, lowering COGS by an estimated 12% versus Europe.\u003c\/p\u003e\n\u003cp\u003eThese Indian facilities undergo regular audits by FDA and EMA; between 2021–2024 they recorded zero critical observations in three major inspections, supporting global GMP compliance.\u003c\/p\u003e\n\u003cp\u003eThe dual-shore model (India plus European R\u0026amp;D\/QA) lets DCA remain price-competitive while keeping quality high, contributing to a 2024 gross margin of about 28% and steady contract wins with Western pharma clients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Multi-Regional Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDishman Carbogen Amcis runs a multi-regional logistics network that shipped clinical and commercial compounds to 35+ countries in 2024, handling temperature-controlled and high-potency materials under GDP and GxP standards.\u003c\/p\u003e\n\u003cp\u003eThey use validated cold-chain packaging, segregated high-potency lanes, and real-time telemetry to keep integrity; average transit-level temperature excursions reported under 0.5% in 2024 audits.\u003c\/p\u003e\n\u003cp\u003eThe network supports on-time delivery for 120+ clinical trials in 2024 and helped preserve revenue by reducing stock-outs, contributing to a 6% rise in CDMO segment bookings year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35+ countries served (2024)\u003c\/li\u003e\n\u003cli\u003e120+ clinical trials supported (2024)\u003c\/li\u003e\n\u003cli\u003e\u0026lt;0.5% temperature excursions (2024 audits)\u003c\/li\u003e\n\u003cli\u003e6% YoY CDMO bookings growth (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompliance-Driven Warehousing and Storage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpcompliance-driven warehousing locates facilities near major transport hubs lead times by up to and enabling faster global deployment for dishman carbogen amcis revenue mix export-dependent these sites meet pharma standards: controlled humidity rh temperature zones high-security containment potent apis lowering spoilage compliance fines. strategic hub placement improves supply-chain reliability cutting stockouts emergency airfreight spend\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30% faster lead times\u003c\/li\u003e\n\u003cli\u003e±2% RH control\u003c\/li\u003e\n\u003cli\u003e25% revenue export exposure\u003c\/li\u003e\n\u003cli\u003e18% lower emergency freight\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pcompliance-driven\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDual-shore CDMO: 20–30% COGS cut, 65% India capacity, 6% YoY bookings (2024)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis uses a dual-shore distribution: Swiss\/UK R\u0026amp;D hubs for early-stage\/clinical work and India\/China for large-scale manufacturing, cutting COGS ~20–30% and supporting 65% group capacity from India (2024); network shipped to 35+ countries, backed 120+ trials, \u0026lt;0.5% temp excursions and drove 6% YoY CDMO bookings growth (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries served\u003c\/td\u003e\n\u003ctd\u003e35+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trials supported\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTemp excursions\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndia capacity\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS savings (dual-shore)\u003c\/td\u003e\n\u003ctd\u003e20–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO bookings YoY\u003c\/td\u003e\n\u003ctd\u003e+6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eDishman Carbogen Amcis 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Dishman Carbogen Amcis 4P's Marketing Mix Analysis you’ll receive instantly after purchase—complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750067417465,"sku":"dishmangroup-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/dishmangroup-marketing-mix.png?v=1772221751","url":"https:\/\/matrixbcg.com\/products\/dishmangroup-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}